US2011189139A1PendingUtilityA1

Hematopoietic Cell E-Selectin/L-Selectin Ligand Glycosylated CD44 Polypeptide

53
Assignee: SACKSTEIN ROBERTPriority: Oct 18, 2000Filed: Jan 24, 2011Published: Aug 4, 2011
Est. expiryOct 18, 2020(expired)· nominal 20-yr term from priority
Inventors:Robert Sackstein
A61P 35/00A61P 9/10A61P 7/00A61P 3/10A61P 35/02A61P 9/00A61P 25/16A61P 29/00A61P 29/02C07K 14/70585C12N 2501/724A61P 21/04A61K 2035/124C12N 2501/90C12N 5/0647C12N 2501/599C12N 2501/59A61P 19/02A61P 11/06A61P 1/04A61P 1/16
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.

Claims

exact text as granted — not AI-modified
1 . An composition comprising a population of cells enriched from blood, said cells expressing a glycosylated CD44 polypeptide, wherein said glycosylated CD44 polypeptide comprises sialylated, fucosylated glycans, and wherein said glycosylated CD44 polypeptide is a ligand for E-selectin, L-selectin, or both. 
     
     
         2 . The composition of  claim 1 , wherein the CD44 polypeptide comprises the amino acid sequence of SEQ ID NO: 1. 
     
     
         3 . The composition of  claim 1 , wherein the cells are stem cells. 
     
     
         4 . A method of treating a hematopoietic disorder in a mammal, the method comprising administering to said mammal a composition comprising the cells of  claim 1 . 
     
     
         5 . A method of treating cancer in a mammal, the method comprising administering to said mammal a composition comprising the cells of  claim 1 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.